Company intelligence / Profile preview

Immedica

Ownership: Private
Development stage: Commercial

Overview

Immedica is a commercial-stage biopharmaceutical company focused on the commercialization of medicines for rare diseases and specialty care. The company has multiple approved products in areas such as rare metabolic disorders, neurology, hematology/oncology. It serves patients in over 50 countries through direct operations or partnerships. Backed by KKR & Impilo investment firms.

Therapeutic areas: Metabolic DisordersRare DiseasesNeurologyHematology
Modalities: small moleculesbiologics
Industry: Biotech

Drug pipeline

4 assets

ganaxolone

Approved

3 more assets in the full pipeline.

Request access →

Partnerships

acquisitionsin-license dealsexclusive distribution agreements with other pharmaceutical companies

Beyond the preview

Go deeper on Immedica.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Immedica.

Explore the full profile